A carregar...
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
We have shown that WT-161, a histone deacetylase 6 (HDAC6) inhibitor, shows remarkable anti-tumor activity in multiple myeloma (MM) in preclinical models. However, its activity in other type of cancers has not yet been shown. In this study, we further evaluated the biologic sequelae of WT161 in brea...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5655183/ https://ncbi.nlm.nih.gov/pubmed/29113288 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19019 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|